Longevity Medicine Implementation: How to Judge Clinic Delivery in 2026
A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
Neko lists its UK scan at £299 and plans to open in New York on September 24, 2026, but no US price is public. Here is what the scan includes and what to verify.
A buyer guide to Human Longevity exam cost, HLI-style diagnostics, genetics, full-body imaging, and the follow-up questions to ask before paying.
A practical guide to the follow-up plan after a longevity assessment: clinical ownership, abnormal findings, referrals, retesting, records, costs, and red flags.
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
A cautious 2026 guide to cognitive decline, longevity clinics, brain-health tests, lifestyle evidence, referral pathways, and red flags.
A buyer guide to longevity blood panels: decision-relevant tests, selective add-ons, exploratory biomarkers, repeat-testing logic, and commercial red flags.
VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
A buyer's guide to full-body MRI at longevity clinics: what it can detect, what it misses, real cost models, false positives, and safer alternatives.
BBC reporting shows a market ranging from ordinary prevention to expensive tests and experimental treatments. This guide separates documented offers from proven health benefit.
A current comparison of Biograph Core and Black: price, tests, clinical touchpoints, exclusions, and the questions to ask before paying for a diagnostic membership.
The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.